IMU
IMUGENE LIMITED
$0.0410
▼ -6.82%
Market cap
$23M
Turnover
$133,114
Last price
$0.0410
Day change
-6.82%
Announcements
14
Range, past year
Open 0.295 · Low 0.010 · Now 0.041 · High 0.460
Open IMU in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
IMU momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-09-28.
Momentum quality
31/100
Wyckoff phase
Downtrend23d
Trend stage
Breakdown
1 Day
-6.8%
1 Week
-12.8%
1 Month
-41.4%
1 Year
-84.8%
RSI
12
Avg daily range
9.3%
IMUGENE LIMITED scores 31 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.
On the Wyckoff cycle it sits in Downtrend, where it has been for 23 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
What stands out
- Trend R² 0.94 — highly linear uptrend
Points to watch
- RSI oversold (12)
- 60d drawdown -61.0%
- High volatility (ATR 9.3%)
- Risk rating: Very High
- Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsIMU announcements
Recent price-sensitive releases.
- 2026-08-28 Appendix 4E and Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-07-31 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-07-27 Third response in concurrent BTKi Cohort of azer-cel Trial Progress Report
- 2026-07-27 CEO Resignation CEO/Managing Director - Appointment Resignation
- 2026-07-07 $11.1 Million Placement Completed to Advance azer-cel
- 2026-07-03 Trading Halt
- 2026-07-01 New Complete Response in the Concurrent BTKi azer-cel Cohort
More Health Care stocks
Most traded in the same sector.